NFX Stock Overview
Operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nuformix plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.00057 |
| 52 Week High | UK£0.0044 |
| 52 Week Low | UK£0.0005 |
| Beta | 1.22 |
| 11 Month Change | 4.55% |
| 3 Month Change | -71.25% |
| 1 Year Change | -79.09% |
| 33 Year Change | -96.89% |
| 5 Year Change | -99.41% |
| Change since IPO | -98.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| NFX | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -8.0% | -4.4% | -1.3% |
| 1Y | -79.1% | 5.6% | 8.9% |
Return vs Industry: NFX underperformed the UK Pharmaceuticals industry which returned 5.6% over the past year.
Return vs Market: NFX underperformed the UK Market which returned 8.9% over the past year.
Price Volatility
| NFX volatility | |
|---|---|
| NFX Average Weekly Movement | 21.3% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: NFX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: NFX's weekly volatility has increased from 14% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3 | n/a | www.nuformix.com |
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Nuformix plc Fundamentals Summary
| NFX fundamental statistics | |
|---|---|
| Market cap | UK£471.10k |
| Earnings (TTM) | -UK£477.88k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs NFX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NFX income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£477.89k |
| Earnings | -UK£477.88k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00058 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NFX perform over the long term?
See historical performance and comparison